-
In a series of consecutive patients with locally advanced rectal cancer, a novel treatment regimen was studied that involved "induction chemotherapy" followed by chemoradiotherapy prior to total mesorectal excision. The investigators found a high local control rate and promising disease-free and overall survival outcomes.
-
Dementia and benzodiazepines; effectiveness of omega-3 fatty acid and Ginkgo biloba supplements; and FDA actions.
-
Among women with early-stage squamous cell carcinoma of the vulva, sentinel node biopsy is a reasonable alternative to inguinal femoral lymphadenectomy. Histological ultrastaging is an important adjuvant to sentinel node assessment for metastatic disease.
-
A 62-year-old Caucasian woman returns to her primary care physician for a follow-up visit after routine colonoscopy and is accompanied by her 63-year-old husband. The gastroenterologist had resected three adenomatous polyps and suggested a repeat colonoscopy in 1 year.
-
The authors performed a prospective cohort study, the contraceptive CHOICE Project, in which women in the St. Louis, Missouri, region received a reversible contraceptive method of their choice for up to 3 years at no cost.
-
Apropos of the recent emphasis on discouraging elective deliveries prior to 39 weeks, a group from Cincinnati embarked on a study to determine whether steroids had any neonatal benefit in patients delivering between 34 and 39 weeks who had immature amniotic fluid lung profiles.
-
In this issue: Lorcaserin for weight loss; statins and fatigue; treatment-resistant gonorrhea; hydrocodone classification changes; USPSTF recommendations; and FDA actions.
-
Researchers from duke university and the university of California, San Francisco enrolled 40 patients with symptoms of overactive bladder (OAB), i.e., urgency, frequency, and/or urge incontinence, and 40 patients with no history of OAB symptoms. The women's view of symptoms and treatments were measured with a utility score.
-
-
Poly(adenosine diphosphate [adp]-ribose) polymerase (PARP) is an enzyme participating in low-fidelity DNA repair of single strand breaks. Pharmacologic inhibition of PARP has shown to be effective in tumors lacking homologous recombination, such as those harboring silencing mutations of BRCA1 and 2.
